$1.54
+0.01 (+0.65%)
Open$1.58
Previous Close$1.53
Day High$1.68
Day Low$1.50
52W High$4.98
52W Low$0.78
Volume—
Avg Volume1.39M
Market Cap200.44M
P/E Ratio—
EPS$-0.73
SectorBiotechnology
Analyst Ratings
Buy
12 analysts
Price Target
+1,170.8% upside
Current
$1.54
$1.54
Target
$19.57
$19.57
$11.03
$19.57 avg
$23.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 83.34M | 114.30M | 66.42M |
| Net Income | -146,085,665 | -180,327,936 | 9.87M |
| Profit Margin | -175.3% | -166.5% | 14.9% |
| EBITDA | -123,725,083 | -161,210,847 | 12.50M |
| Free Cash Flow | — | — | 3.90M |
| Rev Growth | -27.1% | -27.1% | +3.3% |
| Debt/Equity | 3.72 | 3.72 | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |